Real-world disease burden, mortality, and healthcare resource utilization associated with bronchiectasis
Chronic Respiratory Disease · 2025-12 · 22
DOI: 10.1177/14799731241310897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chronic Respiratory Disease, online erschienen am 10.02.2025. Verfasst von Sofia Shoaib und 7 weiteren Autor:innen. Beteiligte Einrichtung: STATinMED, Dallas, TX, USA. Hauptthemen laut MEDLINE: Bronchiectasis, Patient Acceptance of Health Care, Cost of Illness. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Insmed Incorporated.
Abstract (Originalsprache)
Objectives
To assess real-world survival and healthcare resource utilization (HCRU) in US patients with non-cystic fibrosis bronchiectasis (NCFBE).
Methods
This retrospective analysis, using data from the STATinMED RWD Insights database from Jan 2015–Oct 2022, included adults with NCFBE (from Jan 2015–Oct 2021) and non-NCFBE comparators (from Jan 2015–Aug 2020); baseline characteristics were balanced by inverse probability treatment weighting. Outcomes included survival through end of study. HCRU was assessed over 12 months.
Results
117,718 patients with NCFBE and 306,678 comparators were included. Patients with NCFBE had a 77% higher risk of death than comparators (hazard ratio [HR] 1.77 [95% CI 1.74-1.80]). Risk of death was higher among patients aged ≥65 years (vs 18–34 years; HR 11.03 [95% CI 10.36-11.74]), among Black patients (vs White; HR 1.53 [95% CI 1.50-1.55]), and among patients with comorbid COPD (HR 1.42 [95% CI 1.40-1.44]). Patients with NCFBE incurred higher all-cause and respiratory-related HCRU than comparators for outpatient office, outpatient hospital, emergency department (ED), inpatient and respiratory-related pulmonologist visits (all p < .0001); HCRU increased with exacerbations.
Conclusions
Patients with NCFBE have high mortality burden and incur high HCRU, both of which are further increased with exacerbations. Prevention and delay of exacerbations are key areas for improvement of disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- STATinMED, Dallas, TX, USA.
- Insmed Incorporated, Bridgewater, NJ, USA.
- Cleveland Clinic, Cleveland, OH, USA.
ORCID-Profile: Sofia Shoaib
Förderung
- Insmed Incorporated
Zitieren
APA
Shoaib, S., Feliciano, J., Dasenbrook, E. C., Maynard, J., Batchu, L., Mohanty, M., Lauterio, M., & Feld, A. J. (2025). Real-world disease burden, mortality, and healthcare resource utilization associated with bronchiectasis. Chronic Respiratory Disease, 22. https://doi.org/10.1177/14799731241310897
Vancouver
Shoaib S, Feliciano J, Dasenbrook EC, Maynard J, Batchu L, Mohanty M, et al. Real-world disease burden, mortality, and healthcare resource utilization associated with bronchiectasis. Chronic Respiratory Disease. 2025;22. doi:10.1177/14799731241310897
BibTeX
@article{Shoaib2025,
author = {Shoaib, Sofia and Feliciano, Joseph and Dasenbrook, Elliott C and Maynard, Jason and Batchu, Lakshmi and Mohanty, Maitreyee and Lauterio, Melanie and Feld, Alexandra J},
title = {Real-world disease burden, mortality, and healthcare resource utilization associated with bronchiectasis},
journal = {Chronic Respiratory Disease},
year = {2025},
volume = {22},
doi = {10.1177/14799731241310897}
}
EUVIMED